Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2023 16:05 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference

SEATTLE, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
February 14, 2023 16:05 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results

SEATTLE, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
January 23, 2023 16:05 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023

SEATTLE, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
December 27, 2022 16:05 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference

SEATTLE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
December 10, 2022 10:00 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting

Multiple presentations reinforce clonoSEQ’s ability to provide valuable insights for treatment surveillance and clinical decision-makingMore than 30 clonoSEQ-related abstracts to be presented at the...
December 05, 2022 07:30 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting

SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit...
December 01, 2022 07:30 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)

clonoSEQ is the first and only MRD test in DLBCL with Medicare coverage across all lines of therapy, treatment regimens, and timepointsAdaptive now accepts blood samples from DLBCL patients in Streck®...
November 21, 2022 16:05 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference

SEATTLE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
November 21, 2022 07:30 ET | Source: Adaptive Biotechnologies

New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results

>95% of patients who had an MRD test describe that MRD testing helped inform treatment decisions or brought comfort in their treatment journey85% of surveyed patients have heard of MRD testing, yet...
November 03, 2022 16:05 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results

SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right